O îmbunătăţire considerabilă a criteriilor ACR (>50) a fost observată la majoritatea pacienţilor trataţi cu MTX, leflunomidă şi Wobenzym. Acest fapt este confirmat de dinamică pozitivă statistică şi clinică a indicilor (durerea, redoarea, articulaţiile dureroase şi tumefiate, activitatea AR, VSH, HAQ). Utilizarea triplei terapii a scăzut doza medie utilizată de corticosteroizi (de la 5,0 la 2,5 mg), iar 75% au anulat tratamentul cu AINS. Acest rezultat a fost observat la pacienţii selectaţi pe baza ”intent-to-treat”, adică în urma analizei primare a eficacităţii.

Significant improvement on the ACR criteria (> 50) at the end of the study was observed in most patients treated with methotrexate, leflunomide and Wobenzym. This is confirmed by a statistically and clinically significant with the positive dynamics of indicators (pain, stiffness, painful and swollen joints, RA activity, ESR, HAQ). The use of triple therapy decreased the average dose of simultaneous use of corticosteroids (from 5,0 to 2,5 mg) and 76% of patients have canceled NSAIDs. This result was observed in a population of patients selected on the basis of "intent-to-treat", i.e. during the primary effectiveness analysis.